Evommune, Inc. (EVMN)

Evommune, Inc. (EVMN) stock surges to new highs following positive Phase 2a data for EVO301, driving massive increases in social media buzz and creator activity. The company is advancing EVO301 to Phase 2b and exploring new indications, with analyst price targets significantly raised.

About Evommune, Inc.

Evommune, Inc. is a biotechnology company focused on developing therapies for chronic inflammatory diseases.
Evommune, Inc. uses the ticker $EVMN for trading. Listed in the Stocks category.

Insights

Evommune, Inc. (EVMN) market dominance near a 52-week high at [-------].
Evommune, Inc. (EVMN) social dominance hit [------] which is 346% higher than it's daily average.
Evommune, Inc. (EVMN) mentions hit [---] which is 465% higher than it's daily average.
Evommune, Inc. (EVMN) creators hit [---] which is 440% higher than it's daily average.
Evommune, Inc. (EVMN) trading volume is up 4395.61% from the previous month.
Evommune, Inc. (EVMN) market cap is up 94.26% from the previous week.
Evommune, Inc. (EVMN) social dominance is up 5000% from the previous [--] months.
Evommune, Inc. (EVMN) sentiment is up 29.85% from the previous [--] months.
Evommune, Inc. (EVMN) creators is up 1015.63% from the previous week.
Evommune, Inc. (EVMN) engagements is up 3479.95% from the previous week.
Evommune, Inc. (EVMN) mentions is up 398.8% from the previous week.
Evommune, Inc. (EVMN) posts created is up 2429.17% from the previous week.
Evommune, Inc. Creators hit a 52-Week high of [---] for the day
Evommune, Inc. Creators hit an all time of [---] for the day
Evommune, Inc. Mentions hit a 52-Week high of [---] for the day
Evommune, Inc. Mentions hit an all time of [---] for the day
Evommune, Inc. entered the top [--] AltRank™ for the first time
Evommune, Inc. Price hit a 52-Week high of $32.60 for the hour
Evommune, Inc. Price hit an all time of $32.60 for the hour
Evommune, Inc. Engagements hit a 52-Week high of [-------] for the day
Evommune, Inc. Engagements hit an all time of [-------] for the day

Price: $31.60

Price 24-Hour Time-Series Raw Data
The stock price has experienced a dramatic surge, hitting 52-week and all-time highs, primarily driven by the release of positive Phase 2a data for EVO301. This clinical success, coupled with a substantial increase in social media mentions, creator engagement, and overall market buzz, has fueled investor confidence and propelled the stock upwards.

24-Hour: 6.26% 7-Day: 93.98% 30-Day: 87.92%

1-Year High: $31.60 on 2026-02-13
1-Year Low: $15 on 2025-12-18

AltRank: [---]

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
Evommune, Inc. (EVMN) is currently AltRank #363 based on combined combined social and market metrics Daily Average: [-----]
[--] Week: [---] [------]
1-Year High: [-----] on 2026-02-05
1-Year Low: [--] on 2026-02-10

Galaxy Score: [-----]

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] [---]
1-Year High: [--] on 2026-02-10
1-Year Low: [--] on 2026-02-05

Engagements: [-----] (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [-----]
[--] Week: [-------] +3,480%
[--] Month: [-------] +651%
[--] Year: [-------] +571,882%
1-Year High: [-------] on 2026-02-10
1-Year Low: [--] on 2025-12-13

Engagements by network (24h): YouTube: [--] Reddit: [--] X: [-----] TikTok: [--]

Mentions: [---] (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [--]
[--] Week: [-----] +399%
1-Year High: [---] on 2026-02-11
1-Year Low: [--] on 2025-09-25

Mentions by network (24h): YouTube: [--] Reddit: [--] X: [---] TikTok: [--]

Creators: [---] (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
[---] unique social accounts have posts mentioning Evommune, Inc. (EVMN) in the last [--] hours which is up 24% from [---] in the previous [--] hours Daily Average: [--]
[--] Week: [---] +1,016%
1-Year High: [---] on 2026-02-11
1-Year Low: [--] on 2025-09-03

The most influential creators that mention Evommune, Inc. in the last [--] hours

Creator	Rank	Followers	Posts	Engagements
@BiopharmIQ	[--]	[------]	[--]	[---]
@tradingsssss	[--]	[-----]	[--]	[---]
@HOThomasWPhelps	[--]	[-----]	[--]	[---]
@ElSheikh_Stock	[--]	[-----]	[--]	[---]
@BPharmCatalyst	[--]	[------]	[--]	[---]
@CamillusMiura	[--]	[-------]	[--]	[---]
@financebully	[--]	[-----]	[--]	[---]
@JoseRestonVA	[--]	[-----]	[--]	[---]
@DekmarTrades	[--]	[-------]	[--]	[--]
@JustinMorganQ8	[--]	[---]	[--]	[--]

Sentiment: 89%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: 89%
Daily Average: 82%
[--] Week: 100% +20%
[--] Month: 87% +12%
1-Year High: 100% on 2025-10-10
1-Year Low: 33% on 2025-11-29

Most Supportive Themes:

Creator Activity Surge: (38%) Evommune, Inc. has seen a significant increase in active creators, reaching a 52-week and all-time high.
Mention Volume Spike: (177%) Mentions of Evommune, Inc. have also hit a 52-week and all-time high, indicating increased public interest.

Most Critical Themes:

Social Dominance Increase: (749%) Evommune, Inc.'s social dominance has surged significantly, far exceeding its daily average.

Social Dominance: 0.021%

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.021%
Daily Average: 0.00572%
[--] Week: 0.039% +0.02%
[--] Month: 0.026% +0.022%
[--] Year: 0.026% +0.025%
1-Year High: 0.083% on 2026-02-11
1-Year Low: 0.0001% on 2025-09-25

Market Dominance: 0.00115%

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00115%
Daily Average: 0%
1-Year High: 0.00116% on 2026-02-13
1-Year Low: 0.00061% on 2026-02-09

Market Cap: $1,013,499,590

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $1,013,499,590
Daily Average: $658,619,365
[--] Week: $1,013,499,590 +94%
[--] Month: $995,215,616 +88%
1-Year High: $995,215,616 on 2026-02-13
1-Year Low: $525,191,389 on 2026-02-05

Top Evommune, Inc. Social Posts

Top posts by engagements in the last [--] hours

Showing a maximum of [--] top social posts without a LunarCrush subscription.

"$NKTR $CRVS $APGE $KYMR $EVMN why are we even trying to compete with one another 😂 $NKTR $CRVS https://t.co/cJhhh1lPTx $NKTR $CRVS https://t.co/cJhhh1lPTx"
X Link @tradingsssss 2026-02-15T08:45Z [----] followers, [----] engagements

"🧬 Weekly & YTD Biotech Moves Week ending 02/13/26 $XBI: -2.11% ($122.86) 🔴 $IBB: -1.39% ($172.55) 🔴 Year-to-date $XBI: 0.76% 🟢 $IBB: 2.24% 🟢 See image below. 👇 🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/13/26 📈 $EVMN 71% EVO301 Topline data $NKTR 51% REZOLVE-AD Maintenance Data $HUMA 30% New Defense Funding for Blood Vessels $PHIO 24% Positive SMC wrap-up on PH-762 $NVCR 19% FDA Approves Optune https://t.co/RjwPL6kU1b 🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/13/26 📈 $EVMN 71% EVO301 Topline data $NKTR 51%"
X Link @BiopharmIQ 2026-02-14T14:08Z 28.9K followers, [----] engagements

"🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/13/26 📈 $EVMN 71% EVO301 Topline data $NKTR 51% REZOLVE-AD Maintenance Data $HUMA 30% New Defense Funding for Blood Vessels $PHIO 24% Positive SMC wrap-up on PH-762 $NVCR 19% FDA Approves Optune Pax for Cancer 📉 $UPB -47% VALIANT Trial Results $MCRB -42% Program and Corporate Updates $CHRS -20% Pricing of Public Offering $1.75/sh $OKYO -19% Pricing of $20M Offering $1.85/sh $RGNX -14% Regulatory Update on RGX-121 BLA See image below. *** AD momentum continues. $NKTR maintenance data + early Ph2a from $EVMN in a"
X Link @BiopharmIQ 2026-02-14T14:02Z 28.9K followers, [----] engagements

"$ONCY reported significant coordinated insider buying across all executive and board levels on February [----] [----]. Purchases between $0.83 and $0.86 per share signal strong confidence at the current price; shares closed up 26%. $IRON $ONCY $PHIO $CHRS $OKYO $EVMN $AIM $ICLR $INTS $UPB See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/disc-iron-22-complete-response-letter-crl-oncolytics-oncy-27-insider-buys https://www.biopharmcatalyst.com/news/2026/disc-iron-22-complete-response-letter-crl-oncolytics-oncy-27-insider-buys"
X Link @BPharmCatalyst 2026-02-13T21:35Z 30.7K followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing